Breaking News Instant updates and real-time market news.

DHR

Danaher

$76.99

0.555 (0.73%)

15:00
10/19/16
10/19
15:00
10/19/16
15:00

Danaher technical comments ahead of earnings, potential bearish pattern

Ahead of earnings news the key technical feature on the 1-year chart is an irregular bearish head and shoulders pattern that will become active on a move below $75. If the news is a negative surprise the pattern could trigger. Downside potential for the pattern, if it triggers and completes, would be to the $68 to $67 area. If the news is instead a bullish surprise, the first major resistance level would be at the top of the right shoulder of the pattern at $79. If price breaks out above $79, the pattern would be voided. Next resistance levels to watch as potential upside objectives would be at $80.01 and then at $82.64 which is the 52-week high. Above the high next resistance would be at $83.56 and $85.71.

  • 20

    Oct

DHR Danaher
$76.99

0.555 (0.73%)

08/02/16
08/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Salesforce (CRM) initiated with an Overweight at Stephens. 2. Home Depot (HD) and Lowe's (LOW) coverage resumed with a Buy at Stifel. 3. Wix.com (WIX) initiated with an Overweight at Stephens. 4. Barrick Gold (ABX) initiated with a Buy at Citi. 5. Danaher (DHR) initiated with a Market Perform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/16
PIPR
09/06/16
DOWNGRADE
Target $53
PIPR
Neutral
Cepheid downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst William Quirk downgraded Cepheid (CPHD) to Neutral saying the takeover by Danaher (DHR) carries little antitrust risk. The analyst thinks a third-party bidder is unlikely.
09/07/16
BERN
09/07/16
NO CHANGE
BERN
Danaher acquisition should be positive over the mid to long-term, says Bernstein
After Danaher (DHR) agreed to buy Cepheid (CPHD), Bernstein analyst Steven Winoker says that the deal was expensive. However, the analyst says that Cepheid has high recurring revenue, fast growth, and strong synergies with Danaher. Winoker thinks that the deal leaves Danaher well-positioned for growth over the medium to longer term. He keeps a $92 price target and Outperform rating on the stock.
10/12/16
EVER
10/12/16
NO CHANGE
Target $89
EVER
Buy
Danaher acquisition of Phenomenex highly attractive, says Evercore ISI
Evercore ISI analyst Ross Muken is not surprised by Danaher's (DHR) acquisition of Phenomenex saying it is one of the "great consumable assets that remained in Life Science Tools." Muken said the deal terms are "remarkably attractive" and estimates Danaher paid more than $700M for Phenomenex He said revenues are close to $200M, implying an EV/EBITDA multiple in the low to mid-teens, and ROIC north of 10% by year 5, and imply year 1 accretion of 3-5c, and 10-15c by year 5. Muken rates Danaher a Buy with an $89 price target on shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.